Globus Medical, Inc. (NYSE:GMED) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Globus Medical, Inc. (NYSE:GMED) has been given an average recommendation of “Moderate Buy” by the sixteen research firms that are currently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a hold recommendation, nine have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $104.3636.

Several brokerages have issued reports on GMED. Morgan Stanley lifted their target price on shares of Globus Medical from $70.00 to $100.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Truist Financial set a $115.00 target price on shares of Globus Medical in a research report on Wednesday, February 25th. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a research note on Tuesday, December 30th. Wells Fargo & Company boosted their price target on shares of Globus Medical from $98.00 to $104.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Finally, Royal Bank Of Canada upped their price objective on shares of Globus Medical from $92.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th.

Globus Medical News Roundup

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research raised several near‑term and full‑year EPS estimates for GMED — including FY2026 to $4.40 (from $3.85) and FY2027 to $4.66 (from $4.16) — and lifted multiple quarterly forecasts (e.g., Q1 2027 to $1.07, Q2 2027 to $1.14, Q3 2027 to $1.21, Q4 2026 to $1.37). Zacks retains a “Strong‑Buy” rating, implying materially stronger earnings expectations than the current consensus (~$3.44).
• Positive Sentiment: The repeated upward revisions across quarters and fiscal years reinforce an improving earnings trajectory and could justify a higher multiple if revenue growth and margins hold — a supportive factor for medium‑term investors.
• Neutral Sentiment: Market commentary examines how Globus’s Q4 results and developments around competitor Nevro affect the investment thesis; this analysis may help investors assess risk/reward but does not itself change fundamentals. How The Globus Medical (GMED) Investment Story Is Evolving After Q4 Results And Nevro Update

Globus Medical Price Performance

Shares of Globus Medical stock opened at $84.51 on Friday. The business has a 50 day simple moving average of $90.76 and a two-hundred day simple moving average of $78.10. Globus Medical has a 12 month low of $51.79 and a 12 month high of $101.40. The stock has a market capitalization of $11.43 billion, a P/E ratio of 21.45, a PEG ratio of 2.04 and a beta of 1.05.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Tuesday, February 24th. The medical device company reported $1.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.06 by $0.22. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.The firm had revenue of $826.42 million for the quarter, compared to analyst estimates of $803.29 million. During the same period in the previous year, the company posted $0.84 earnings per share. The business’s revenue was up 25.7% on a year-over-year basis. As a group, research analysts anticipate that Globus Medical will post 3.44 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Leslie V. Norwalk sold 2,000 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total value of $202,200.00. Following the completion of the sale, the director owned 10,419 shares of the company’s stock, valued at approximately $1,053,360.90. This trade represents a 16.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kyle Kline sold 3,594 shares of Globus Medical stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total value of $363,353.40. The SEC filing for this sale provides additional information. Insiders have sold 35,594 shares of company stock valued at $3,332,253 in the last ninety days. 18.51% of the stock is currently owned by corporate insiders.

Institutional Trading of Globus Medical

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. SBI Securities Co. Ltd. lifted its position in Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after buying an additional 167 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Globus Medical by 2.8% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 6,316 shares of the medical device company’s stock worth $375,000 after buying an additional 170 shares during the period. Parallel Advisors LLC increased its position in shares of Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after acquiring an additional 173 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Globus Medical by 14.7% in the 3rd quarter. GAMMA Investing LLC now owns 1,438 shares of the medical device company’s stock valued at $82,000 after acquiring an additional 184 shares during the period. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 197 shares during the period. 95.16% of the stock is owned by institutional investors and hedge funds.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.